Aura Health Inc. (the “Company” or “Aura”) (CSE: BUZZ) wishes to announce the following changes to its board of directors (the “Board”). Effective immediately, Joel Freudman has been appointed to the Board as an independent director and Chair of the Board’s Audit Committee, subject to regulatory approval by the Canadian Securities Exchange. Mr. Freudman is the President of Resurgent Capital Corp., a Toronto-based merchant bank focused on undervalued micro-cap Canadian public companies. He is also President and CEO and a Director of Trius Investments Inc. (TSXV:TRUH). Mr. Freudman started his career in private practice as a securities and M&A lawyer and subsequently transitioned to in-house legal counsel for various wealth management firms and major Canadian financial institutions. Mr. Freudman is a member of the Law Society of Ontario, holds a Juris Doctor degree from the University of Western Ontario and a Bachelor of Commerce degree from the University of Toronto.

In association with the appointment of Mr. Freudman, Jimmy Gravel has resigned from the Board in order to pursue other business opportunities, effective immediately. The Board would like to thank Mr. Gravel for his service to the Company and wishes him the best in his future endeavours.


Daniel Cohen, CEO of Aura, commented: “We are happy to add Joel to the Board for his corporate governance and transactional expertise, which will help as we accelerate our international growth strategy. At the same time, we also want to sincerely thank Jimmy Gravel for his contributions to the Company and wish him the best in his future endeavours.”

About Aura Health Inc.
Aura, through its wholly-owned Delaware subsidiary Green Global Properties Inc. (“Green Global”), owns a 30% interest in four medical marijuana clinics in Las Vegas, Nevada; Mesa, Arizona; Tucson, Arizona; and Hollywood, Florida. Green Global has an option to increase its interest in each such clinic (other than the Nevada clinic) to 51%.

Aura’s common shares trade on the Canadian Securities Exchange under the symbol “BUZZ”. For updates on the Company’s activities and to see its investor presentation, please visit Aura’s web site at www.aurahealthinc.com.

For further information, please contact:

Daniel Cohen, CEO – (647) 202-1824

David Posner, Director and Chairman – (647) 985-6727

Caution Regarding Forward-Looking Information:

This news release contains “forward-looking information” within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by words and phrases such as “plans”, “expects” “scheduled”, “estimates”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken or occur. Forward-looking information in this news release includes, without limitation, statements regarding the Company’s future expansion plans. This forward-looking information consists of disclosure regarding possible events, conditions or results, and is based on numerous assumptions, including that the new director appointment will be approved and that Aura will be able to successfully develop and execute its plans for international growth.

The forward-looking information in this news release is subject to numerous risks and uncertainties that may cause Aura’s actual results or performance to differ materially from those expressed or implied by such forward-looking information, including but not limited to: regulatory approval processes; challenges in business performance and execution; and other risks described in the Company’s continuous disclosure documents. Accordingly, investors should not place undue reliance on such forward-looking information. The Company does not undertake to update any forward-looking information herein, except as may be required by applicable securities laws.

Source: globenewswire.com

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less